

CD19 (B-Lymphocyte Marker) Antibody

Mouse Monoclonal Antibody [Clone CVID3/429]



Catalog No	Format	Size
930-MSM3-P0	Purified Ab with BSA and Azide	200ug/ml
930-MSM3-P1	Purified Ab with BSA and Azide	200ug/ml
930-MSM3-P1ABX	Purified Ab WITHOUT BSA and Azide	1.0mg/ml

Applications	Tested Dillution
Flow Cytometry (Flow)	1-2ug/million cells
Immunofluorescence (IF)	1-3ug/ml

Product Details	
Clone	CVID3/429
Gene Name	CD19
Immunogen	Recombinant full-length human CD19 protein
Host	Mouse
Clonality	Monoclonal
Isotype / Light Chain	IgG1 / Kappa
Mol. Weight of Antigen	95kDa
Cellular Localization	Cell membrane, Membrane raft
Species Reactivity	Chimpanzee, Human, Monkey
Positive Control	hPBL, lymph node or spleen., Raji cells, Tonsil


**Optimal dilution for a specific application should be determined.*

Product Images for CD19 (B-Lymphocyte Marker) Antibody




Immunofluorescent staining of Raji cells. CD19 Mouse Monoclonal Antibody (CVID3/429) followed by goat anti-Mouse IgG-CF488 (Green). The nuclear counterstain is Reddot (Red)

SDS-PAGE Analysis of Purified CD19 Mouse Monoclonal Antibody (CVID3/429). Confirmation of Purity and Integrity of Antibody.



Flow cytometry analysis of lymphocyte-gated PBMCs unstained (gray) or stained with CF405S-labeled CD19 mouse monoclonal antibody (CVID3/429) (violet).



Flow Cytometric Analysis of Raji cells. CD19 Mouse Monoclonal Antibody (CVID3/429) followed by goat anti-Mouse IgG-CF488 (Blue); Isotype Control (Red).

Specificity & Comments

CD19 is a transmembrane glycoprotein that contains two extracellular immunoglobulin-like domains. CD19 is present in both benign and malignant B-cells and is considered to be the most reliable surface marker of this lineage over a wide range of maturational stages. In normal lymphoid tissue, CD19 is observed in germinal centers, in mantle zone cells, and in scattered cells of the inter-follicular areas. Anti-CD19 exhibits an overall immunoreactivity pattern similar to those of the antibodies against CD20 and CD22. However, in contrast to CD20, expression of CD19 is continuous throughout B-cell development and through terminal differentiation of B-cells into plasma cells. Anti-CD19 positivity is seen in the vast majority of B-cell neoplasms commonly at a lower intensity than normal B-cell counterparts. Plasma cell neoplasms are nearly always negative, as are T-cell neoplasms.

Research Areas

Cardiovascular, Immunology, B Cell Markers, Complement System, Hematopoietic Stem Cells, Immune checkpoint, Infectious Disease, Mesenchymal Stem Cell Differentiation, Signal Transduction

Known Applications & Suggested Dilutions

Flow Cytometry (1-2ug/million cells) | ,Immunofluorescence (1-2ug/ml) | ,Optimal dilution for a specific application should be determined.

Limitations and Warranty

This antibody is available for research use only and is not approved for use in diagnosis.

There are no warranties, expressed or implied, which extend beyond this description. Company is not liable for any personal injury or economic loss resulting from this product.

Supplied As

200ug/ml of Ab Purified from Bioreactor Concentrate by Protein A/G. Prepared in 10mM PBS with 0.05% BSA & 0.05% azide. Also available WITHOUT BSA & azide at 1.0mg/ml.

Storage and Stability

Antibody with azide - store at 2 to 8°C. Antibody without azide - store at -20 to -80°C. Antibody is stable for 24 months. Non-hazardous. No MSDS required.